LB Pharmaceuticals to Participate in Upcoming June Investor Events
LB Pharmaceuticals (Nasdaq:LBRX) will participate in two June 2026 investor conferences.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
LB Pharmaceuticals (Nasdaq:LBRX) will participate in two June 2026 investor conferences. Executives present at the Jefferies Global Healthcare Conference on June 4, 2026 at 2:35 p.m. ET and at the H.C. Wainwright 7th Annual Neuro Perspectives Hybrid Conference on June 16, 2026.
Webcasts and replays will be accessible on the company’s Investors > Events webpage.
Details
News Market Reaction – LBRX
On May 29, the first trading day after this news, LBRX closed 1.60% above the previous close.
Data tracked by StockTitan Argus for the May 29 session.
Key Figures
- Jefferies conference date
- June 4, 2026
- Jefferies Global Healthcare Conference presentation date
- Jefferies conference time
- 2:35 p.m. ET
- Scheduled presentation time at Jefferies conference
- H.C. Wainwright conference date
- June 16, 2026
- H.C. Wainwright Neuro Perspectives Conference
Historical Context
-
Q1 2026 financials, strong cash position, and late-stage pipeline progress.
-
Phase 2 NOVA-1 schizophrenia results published in JAMA Psychiatry.
-
Announcement of presentation at Needham Virtual Healthcare Conference.
-
New Phase 2 NOVA-1 cognition analyses presented at SIRS congress.
-
FY 2025 results and advancement of LB-102 into late-stage development.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
NEW YORK, May 28, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), a late-stage biopharmaceutical company developing novel therapies for schizophrenia, bipolar depression, adjunctive treatment of major depressive disorder, and other neuropsychiatric diseases, today announced that members of its executive team, will present and participate in the following upcoming investor conferences:
Jefferies Global Healthcare Conference
Date: Thursday, June 4, 2026
Time: 2:35 p.m. ET
H.C. Wainwright 7th Annual Neuro Perspectives Hybrid Conference
Date: Tuesday, June 16, 2026
Time: Presentation available on the LB Pharmaceuticals website
The webcasts for the presentation and fireside chat will be available on the “Investors” page section under the “Events” section of the Company’s website at https://ir.lbpharma.us/, where a replay of the webcasts will be archived.
About LB Pharmaceuticals
LB Pharmaceuticals is a late-stage biopharmaceutical company developing novel therapies for the treatment of schizophrenia, bipolar depression, adjunctive treatment of major depressive disorder and other neuropsychiatric diseases. The Company is building a pipeline that leverages the broad therapeutic potential of its lead product candidate, LB-102, which the Company believes has the opportunity to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102, if approved, has the potential to become a mainstay of psychiatric practice by offering a balanced clinical activity and tolerability profile that provides a potentially attractive alternative to branded and generic therapeutics for the treatment of a broad range of neuropsychiatric diseases.
Media and Investor Contact:
Ellen Rose
erose@lbpharma.us
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.